Bevacizumab

ArtNr	HY-P9906-50mg
Hersteller	MedChem Express
CAS-Nr.	216974-75-3
Menge	50 mg
Quantity options	100 mg 10 mg 1 mg 25 mg 50 mg 5 mg
Kategorie	Antibodies Primary Antibodies
Typ	Antibody Monoclonal
Specific against	other
Purity	99.0
Citations	[1]Tan H, et al. 99mTc-labeled bevacizumab for detecting atherosclerotic plaque linked to plaque neovascularization and monitoring antiangiogenic effects of treatment in ApoE-/-mice. Sci Rep. 2017 Jun 14;7(1):3504.\|[2]Wang Q, et al. Pharmacological characteristics and efficacy of a novel anti-angiogenic antibody FD006 in corneal neovascularization. BMC Biotechnol. 2014 Feb 27;14:17.\|[3]Di Mauro C, et al. Hedgehog signalling pathway orchestrates angiogenesis in triple-negative breast cancers. Br J Cancer. 2017 May 23;116(11):1425-1435. ACS Appl Mater Interfaces. 2024 Sep 11;16(36):47075-47088. Adv Sci (Weinh). 2023 Jun;10(17):e2205915. Adv Sci (Weinh). 2025 Sep;12(33):e02015. Anal Chim Acta. 2021 Apr 15:1154:338306. Apoptosis. 2025 Feb;30(1-2):16-34. Autophagy. 2025 Mar;21(3):619-638. Biochem Pharmacol. 2024 Feb:220:115991. Biomaterials. 2024 Jul:308:122550. Bone Res. 2024 Apr 10;12(1):24. Cancer Res. 2024 Jun 4;84(11):1781-1798. Cell Death Dis. 2020 Jan 23;11(1):55. Cell Death Dis. 2025 Oct 24;16(1):751. Cell Rep. 2023 Apr 5;42(4):112328. Cell Signal. 2024 Aug 13:111346. Commun Med (Lond). 2025 Nov 18;5(1):478. EBioMedicine. 2019 Sep. Int J Biol Sci. 2022 Jan 1;18(3):942-955. Int J Mol Sci. 2023 Jul 21;24(14):11766. Int J Nanomedicine. 2024 Jul 16:19:7165-7183. J Clin Oncol. 2024 Oct 30:JCO2401266. J Ethnopharmacol. 2022 Jan 30:283:114667. J Exp Clin Cancer Res. 2023 Mar 30;42(1):77. J Extracell Vesicles. 2019 Jun 17;8(1):1629865. J Mol Histol. 2025 Oct 22;56(6):350. J Pharm Biomed Anal. 2021 May 10:198:114015. J Transl Med. 2025 Apr 12;23(1):437. J Transl Med. 2025 Jan 23;23(1):109. Mater Today Bio. 2023 Sep 16:23:100800. Mater Today Bio. 2025 May 29:33:101917. Mol Carcinog. 2019 Dec;58(12):2316-2326. Mol Pharm. 2025 Feb 3;22(2):972-983. Nat Commun. 2025 Nov 18;16(1):10096. Nucleic Acid Ther. 2020 Dec;30(6):365-378. Pediatr Res. 2025 Oct 27. Pharmacol Res. 2024 May 18:107218. Phytomedicine. 2025 Oct 3:148:157358. PLoS Pathog. 2023 Jan 18;19(1):e1011077. Ren Fail. 2025 Dec;47(1):2561784. Res Sq. 2025 May 29. Research Square Preprint. 2020 Jun. Research Square Print. 2022 Jun. Sci Rep. 2025 Jul 1;15(1):20778. Sci Rep. 2019 Nov 18;9(1):16954. Theranostics. 2024 Jan 20;14(3):1312-1324. Vascul Pharmacol. 2022 Dec:147:107126. Brain Res. 2026 Jan 1:1870:150069.
Smiles	[Bevacizumab]
ECLASS 10.1	42030590
ECLASS 11.0	42030590
UNSPSC	12352203
Alias	Anti-Human VEGF,Humanized Antibody
Versandbedingung	Gekühlt
Lieferbar
Manufacturer - Type	Inhibitory Antibodies
Manufacturer - Applications	Cancer-Kinase/protease
Manufacturer - Category	Antibody; Reference compound / Active compounds; API; Inhibitory Antibodies
Manufacturer - Targets	VEGFR
Shipping Temperature	Blue Ice
Storage Conditions	Store at 4°C for 2 years, do not freeze
Molecular Weight	(146.56 kDa)
Product Description	Bevacizumab, a humanized IgG1 monoclonal antibody, specifically binds to all VEGF-A isoforms with high affinity.
Manufacturer - Research Area	Cancer
Solubility	H2O
Manufacturer - Pathway	Protein Tyrosine Kinase/RTK
Clinical information	Launched
UNSPSC Code	12352203

Hinweis: Die dargestellten Informationen und Dokumente (Bedienungsanleitung, Produktdatenblatt, Sicherheitsdatenblatt und Analysezertifikat) entsprechen unserem letzten Update und sollten lediglich der Orientierung dienen. Wir übernehmen keine Garantie für die Aktualität. Für spezifische Anforderungen bitten wir Sie, uns eine Anfrage zu stellen.

Alle Produkte sind nur für Forschungszwecke bestimmt. Nicht für den menschlichen, tierärztlichen oder therapeutischen Gebrauch.